Shares of US clinical-stage biotech AnaptysBio (Nasdaq: ANAB) fell as much as 13% in after-hours trading Monday, as it announced that top-line data from its Phase II clinical trial of imsidolimab, formerly known as ANB019, for the treatment of moderate-to-severe acne, also known as the ACORN trial, did not demonstrate efficacy over placebo on primary or secondary endpoints.
AnaptysBio continues to advance three wholly-owned pipeline programs through clinical development. While clinical development is being discontinued in acne, imsidolimab demonstrated efficacy and safety in the GALLOP Phase II trial in generalized pustular psoriasis (GPP) and enrollment of the GEMINI-1 GPP Phase III trial is ongoing and top-line data from the imsidolimab HARP Phase II trial in moderate-to-severe hidradenitis suppurativa is anticipated during the second half of 2022.
Beyond imsidolimab, enrollment is ongoing in the AZURE Phase II trial of rosnilimab, a PD-1 agonist antibody, in moderate-to-severe alopecia areata and healthy volunteer Phase I top-line data for ANB032, a BTLA modulator antibody, is anticipated in the second quarter of 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze